MTE #13: Novel Modalities for Hepatitis B–Related Hepatocellular Screening and Surveillance (Ticketed)

Hepatitis B virus (HBV)–related hepatocellular carcinoma (HCC) remains the most common complication of chronic HBV infection. Treatment with HBV antiviral therapy has been shown to reduce the risk of HCC but does not completely eliminate it. Currrent screening and surveillance strategies that require the use of abdominal ultrasound, with or without alpha-fetoprotein testing, are suboptimal. Therefore, novel approaches to HCC screening and surveillance are urgently needed in clincial practice.  Experts review recommendations from current American Association for the Study of Liver Diseases guidelines and discuss methods to refine screening and surveillance strategies for persons living with chronic HBV infection. Speakers also highlight novel biomarkers and imaging-based modallities that show promise for improving early detection of HCC in persons living with chronic HBV infection. Data from clinical studies are reviewed and translated into practice points for the clinician.